Three different trials on Minnesota hog farms resulting in encouraging evidence for the success of Aptimmune‘s Barricade vaccines. Dr. Chris Sievers, associate veterinarian at the Swine Vet Center in Minnesota presented on the trials at the 2018 Aptimmune Scientific Symposium. “The exciting thing with Aptimmune is we have a vaccine that’s killed that’s showing some effectiveness,” said Sievers. “I should … Read More
Reducing Mortality with Barricade PRRS
Participants in the 2018 Aptimmune Scientific Symposium heard some real world examples of how Barricade PRRS is helping farmers to fight the illness in their herds. Dr. Natalie Baker shared evidence of the vaccine’s success after Porcine Reproductive and Respiratory Syndrome (PRRS) broke on an Indiana operation in April 2017. “We followed these pigs out and looked at mortality data … Read More
New Swine Inactivated Mucosal Flu A Virus Vaccine from Aptimmune
Aptimmune Biologics introduces the industry’s first inactivated mucosal influenza A virus in swine (IAV-S) vaccine administered via nasal spray. Aptimmune’s IAV-S vaccine utilizes the BARRICADE™ proprietary vaccine formulation that gives swine producers and veterinarians a completely different approach to conventional inactivated injectable and live virus vaccines for safely preventing and managing respiratory disease. This inactivated mucosal vaccine is a new … Read More
AgriLabs New Custom Vaccine Option for Swine
AgriLabs® has introduced a new innovative custom vaccine option for swine veterinarians and producers. It combines the benefits of herd-specific autogenous vaccines with proprietary production processes and ENABL® adjuvant technology designed to improve vaccine performance. “The custom vaccine market has seen little innovation in recent years despite a growing number of companies,” says Sean O’Hare, executive vice president of AgriLabs. … Read More
The ZMAC Difference in Aptimmune’s Barricade
The ZMAC cell line is one piece to the Barricade puzzle. Recently launched by Aptimmune, Barricade is the latest vaccine formulation technology. Aptimmune’s Dr. Gabriela Calzada-Nova, specializes in viral immunology and takes us through the ZMAC difference when it comes to the fight against PRRS in swine houses across the country. “ZMAC cells are wonderful sub-strates that allow PRRS virus … Read More
Mucosal Immunity from Aptimmune – Filling A Gap
Filling a market void is what Aptimmune Biologics has done with their launch of Barricade. Since 1996 when the first PRRS hit the market there have been great successes. However, the disease continues to evolve and vaccine solutions have not kept up with the challenges the virus has brought to us. Dr. Bob Nordgren, Aix Bio Consulting, said in the … Read More
Aptimmune’s Barricade, A Vaccine Formulation Tech for Pigs
Founded in 2010 by Dr. Federico Zuckermann, Aptimmune Biologics has meshed together some of the best in class technologies into a product able to deliver revolutionary results to producers. Barricade is the latest in vaccine formulation technology brought to producers exclusively by Aptimmune. Launched as an autogenous product, the intranasal mucosal inactivated vaccine for PRRS, brings together the best concepts … Read More
Improve Immune Response With Innovator Vaccines
Equine vaccine combinations that include West Nile virus and equine influenza/equine herpesvirus (rhino) antigens in a single formulation are convenient, but they may sacrifice a horse’s immunity, according to research. A study showed that separate administration of Zoetis’ West Nile-Innovator and Fluvac Innovator generated four times the immune response to West Nile virus than was produced by a big one-shot … Read More
Aptimmune Part of The Yield Lab Ag Tech Accelerator
Chosen from among 120 applicants, Aptimmune Biologics was selected by The Yield Lab to participate in a nine-month program designed to support emerging ag tech companies. Aptimmune Biologics is developing and will soon launch innovative autogenous mucosal vaccines to help producers prevent major swine viral diseases. “We are honored that The Yield Lab has chosen to invest in Aptimmune and … Read More
Merck Receives USDA License for BOVILIS CORONAVIRUS
The 2016 World Dairy Expo was the perfect venue for Merck Animal Health to debut their BOVILIS® CORONAVIRUS, the 1st USDA-approved modified-live intranasal vaccine to aid in reduction of enteric disease caused by Bovine Coronavirus (BCV). BCV is commonly transferred by animals during periods of stress, including shipping, parturition, cold weather, commingling or delivery to a backgrounding facility or feedyard. … Read More